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Aim. To raise the awareness of a hypercoagulability state as it is often associated with the different types of malignancies. Venous
thromboembolism is a frequent complication in these patients, and usually it happens after the diagnosis of cancer is confirmed.
However, hypercoagulability disorders presenting as the first symptoms or signs in the cancer patients have rarely been reported.
Furthermore, arterial thrombosis is extremely rare even in cancer patients.Method. Review of the case characteristics and literature
review. Results. We present a case of 39-year-old woman who was admitted to our hospital because of intermittent claudication in
the right lower extremity. CT angiography revealed multiple thrombi in the arterial system starting from the left ventricle, followed
by a thrombus in the distal part of the descending aorta, in the superior mesenteric artery, and in the right popliteal artery. Further
investigation of this young patient with no risk factors for hypercoagulable state and no other comorbidities led to complete work-
up including diagnostic evaluation for malignancy. The suspicion was confirmed after performing upper endoscopy with biopsy,
which revealed malignant neoplasm of the stomach. Conclusion. Whenever a patient suffers hypercoagulability disorders, even
arterial thrombosis, we should always consider the possibility of a cancer.
1. Introduction
Thromboembolic complications affect approximately 15% of
the cancer patients [1]. The oldest theory of this hypercoag-
ulable state was established 150 years ago, when Trousseau
in 1865 first described migratory thrombosis as the first
manifestation of occult gastric cancer [2]. Today this concept
of “Trousseau’s syndrome” is used to describe not onlymigra-
tory thrombosis that precedes the diagnosis of occult cancer
but also any “hypercoagulable state associatedwithmalignant
cancer” [3, 4].
Although the underlying biochemical mechanisms are
poorly understood they are likely to be multiple and, proba-
bly, synergistic [5]. It is believed that this hypercoagulable or
prothrombotic state of malignancy occurs due to the ability
of tumor cells to activate the coagulation system [6]. The
cancer cells have the ability to produce and secrete procoagu-
lant/fibrinolytic substances and inflammatory cytokines, and
the interaction between tumor cells and blood cells (mono-
cytes, platelets, and neutrophils) or vascular cells can activate
the coagulation cascade. Other mechanisms of thrombus
promotion in malignancy include nonspecific factors such
as the generation of acute phase reactants and necrosis,
abnormal protein metabolism (i.e., paraproteinemia), and
hemodynamic compromise (i.e., stasis) [6]. As a paraneo-
plastic syndrome, this disorder is known to be frequently
associated with a variety of malignancies, including the ones
that are affecting the gastrointestinal system.
Deep vein thrombosis (DVT) and pulmonary embolism
(PE) are the two most common thromboembolic complica-
tions in cancer [7], but arterial thrombosis in the set of sec-
ondary hypercoagulable state due to malignancy is extremely
rare [8].The percent of the cases where arterial thrombosis is
a complication of this hypercoagulability remains unknown.
The large proportion of terminal events in neoplastic
diseases is thrombotic, leading to the hypothesis that can-
cer is a prothrombotic disease [5]. Furthermore, many of
the standard chemotherapies in cancer are prothrombotic.
Accordingly, thromboprophylaxis in cancer with heparins or
oral anticoagulation (such as warfarin), especially in high risk
groups (such as those who are immobile and on high doses
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Figure 1: Left ventricular thrombus.
of chemotherapy), may be an important therapy [5]. We are
describing such a clinical case.
2. Case Presentation
Medical history is as follows: 39-years-old woman was hos-
pitalized in our clinic with signs of intermittent claudication
(Fountain IIb) in the right lower extremity. The symptoms
started 15 days prior to admission andwere accompaniedwith
unpleasant tingling sensation in the leg. The patient sought
medical help in a hospital facility, but no extensive diagnostic
and therapeutic procedures were undertaken, and she was
recommended to contact a cardiologist to perform Doppler
ultrasound of the lower limbs. Although the general aspect of
the patient alluded to a healthy individual, a more detailed
history uncovered severe weight loss of 15 kg in the last 5
months. She had no risk factors for atherosclerosis and has
never been hospitalized prior to this event. Physical exam-
ination revealed a cold, marmorized right lower extremity
with an absent pulse starting at the level of the right popliteal
artery. The laboratory analyses revealed sideropenic anemia
(hemoglobin of 9.8 g/dL and mean corpuscular volume of
73 fL) with high erythrocyte sedimentation rate (66/120),
elevatedC reactive protein (118mg/L), and elevatedD-dimers
(1.10 micrgr/mL). Other biochemical parameters were within
normal range.The echocardiographic examination visualised
large mobile structure in the left ventricle attached to the lat-
eral wall with dimensions 24×14mmwith echocardiographic
characteristics typical of thrombotic material.
The possibility of arterial thrombosis led to the further
diagnosticwork-up towardsCT angiography. It revealedmul-
tiple arterial thrombi starting with a big floating thrombus in
Figure 2: Thrombus in the descending aorta.
the left ventricle (Figure 1), followed by intramural thrombus
in the distal descending aorta (with diameter of 9mm)
(Figure 2) and thrombus in the superior mesenteric artery
and the right popliteal artery (Figure 3). The CT scan also
incidentally discovered the presence of enlarged lymph nodes
in the paraaortic (with largest diameter of 10mm) and
gastroepiploic region. After a consultation with a vascular
surgery team and a given recommendation for conservative
treatment, the patient was treated with UFH intravenously
for 9 days and then overlap and finally switched to warfarin.
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Figure 3: Thromboembolism leading to occlusion of the right
popliteal artery.
11 days later, the control echocardiogram did not show any
residual thrombotic material in the left chamber. The control
hemostasis was in the normal range, with international
normalized ratio (INR) kept in the range of 2-3.The presence
of abdominal lymphadenopathy accompanied with hyper-
coagulable state of unknown origin, severe weight loss, and
sideropenic anemia with high sedimentation rate raised the
suspicion of undiscovered malignancy. An upper endoscopy
was performed and it discovered ulcer like excavation with
irregularly formed edges located on the lesser curvature with
dimension of 30mm and three slightly elevated lesions in
the proximal part of the gastric corpus. The macroscopic
features of these changes were highly suspicious for gastric
carcinoma, and the diagnosis was confirmed with biopsy. It
revealed the presence of moderately differentiated invasive
gastric adenocarcinoma with malignant cells with nuclear
grade 2. Immunohistochemical analysis was also performed
(HER2/neu(+)). The biopsy suggested an intestinal type of
cancer according to Lauren’s classification of gastric cancer.
After consultation with abdominal surgeon, our patient was
directed to the Digestive Surgery Department for estimation
of future treatment of the underlying condition.
3. Discussion
Thromboembolic disease affects about 15% of cancer patients
and remains a challenge for modern medicine for both
prophylaxis and treatment [1]. The association of malig-
nancy and hypercoagulable state has been researched for
decades but the biochemical mechanisms are not yet fully
understood [7]. There is evidence that certain cancers are
more likely to be prothrombotic, and this is likely to be
influenced by disease staging and bedrest, as well as ther-
apeutic intervention [6]. The current findings indicate that
tumor cells are directly prothrombotic and have the ability to
produce and secrete procoagulant/fibrinolytic substances and
inflammatory cytokines; on the other hand the normal host
cells may be also considered as a second response against the
cancer cells [5, 6]. Additionally increased levels of coagulation
factors, blood turbulence, coexisting inflammatory diseases,
use of growth factors, chemotherapy, and irradiation therapy
may all induce thrombosis [5]. Examples of molecules elabo-
rated by cancer cells that can predispose to disordered coag-
ulation include tissue factor, a vitamin K-dependent cysteine
protease that activates factor X, and a mucin procoagulant
that activates prothrombin [9].This state is the second leading
cause of death for cancer patients although, in many of these
patients, it represents only one of the many complications of
the end-stage disease [10]. A hypercoagulable state related to
a cancer is a well-known risk factor for venous thrombosis,
but there are fewer data on arterial thrombosis [9]. Arterial
thrombosis as a firstmanifestation of cancer is extremely rare.
Javid et al. made a study on 20 patients with malignancy and
arterial thrombosis and the most common malignancy was
breast cancer [11]. Rigdon [12] reported three patients who
developed acute arterial thrombosis in extremities without
significant atherosclerosis in arms or legs but who were
subsequently discovered to have an occult malignancy (none
of these patients were diagnosed with gastric adenocarci-
noma). In our case, our patient had symptoms for 5 months
before admission but she did not consult a physician due
to the uncharacteristic nature of the symptoms. The diffuse
thromboembolism, which affected only the arterial system,
led to a broad diagnostic work-up for hypercoagulable state,
but the laboratory findings, the medical history of weight
loss, and the incidentally discovered lymphadenopathy were
of great importance for further evaluation in direction of
occult malignancy. The upper endoscopy and the biopsy
confirmed the suspicion and the patient was treated with
anticoagulant therapy. Nowadays recommendations suggest
that these patients should receive an anticoagulation therapy
[8]. Surgical thrombectomy has an indication in selected
cases of recurrent embolism or persistent thrombus despite
proper anticoagulation. Patients with a threatened extremity
should be treated with emergent surgical revascularization
to resolve the symptoms of acute distal embolization, in
addition to perioperative intravenous heparin therapy with
conversion to oral anticoagulation [8].
4. Conclusion
Arterial thrombosis in patients without atherosclerosis and
known CVD risk factors should always raise the suspicion
of occult malignancy. Complete diagnostic investigation is
obligatory and if no other reason for hypercoagulability state
could be found screening for malignant cause should be
undertaken.
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